Skip to main content

Table 1 Phase 111 clinical trials of anti-VEGF monoclonal antibody agents in advanced gastric cancer

From: Treatment outcome of anti-angiogenesis through VEGF-pathway in the management of gastric cancer: a systematic review of phase II and III clinical trials

Variable AVAGAST trial AVATAR trial REGARD trial RAINBOW trial
Authors Ohtsu et al. Shen et al. Fuchs et al. Wilke et al.
Number of patients 774 202 355 665
 1st-arm 387 100 238 330
 2nd-arm 387 102 117 335
Setting 1st-line 1st-line 2nd-line 2nd-line
Treatment regimens
 1st-arm CT + Bev CT + Bev Ram + BSC PTX + Ram
 2nd-arm CT + placebo CT + placebo BSC PTX + placebo
ORR (%)
 1st-arm (n/%) 46% 41% 3% 28%
 2nd-arm 34.4% 34% 3% 16%
 HR (95% CI) 8.1 (0.6–16.6) 7.02 (8.3–22.4)   
 p value 0.0315 0.34   
TTP/PFS (in months)
 1st-arm 6.7 6.3 2.1 4.40
 2nd-arm 5.3 6.0 1.3 2.86
 HR (95% CI) 0.80 (0.68–0.93) 0.89 (0.66–1.21) 0.483 (0.376–0.620) 0.635 (0.536–0.752
 p value 0.0037 0.47 0.0001 0.0001
OS (in months)
 1st-arm 12.1 10.5 5.2 9.63
 2nd-arm 10.1 11.4 3.8 7.26
 HR (95% CI) 0.87 (0.73–1.03) 1.11 (0.79–156) 0.77 (0.603–0.998 0.807 (0.678–0.962)
 p value 0.1002 0.56 0.047 0.0169
  1. ORR median overall response rate, TTP median time to progression, PFS median progression-free survival, OS median overall survival, T capecitabine, C cisplatin, Bev bevacizumab, HR hazard ratio, CI confidence interval, Ram ramucirumab, BSC best supportive care, PTX paclitaxel